findmyKOL
Clinical trialNCT03474549CompletedInterventional

Treatment With Intent to Generate Endovascular Reperfusion

SponsorRapid MedicalEnrollment160Ischemic Stroke
View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Tigertriever is a CE marked mechanical revascularization device indicated to restore blood flow by removing thrombus from a large intracranial vessel in patients experiencing ischemic stroke within 8 hours of symptom onset. Patients who are ineligible for IV t-PA or who fail IV t-PA therapy are candidates for treatment. The objective of the TIGER Study is to evaluate the safety and effectiveness of the Tigertriever device in restoring blood flow in the neurovasculature by removing thrombus in patients experiencing ischemic stroke due to a large vessel occlusion (LVO). This study is designed to support substantial equivalence to approved and marketed products such as the Solitaire or Trevo Retriever.
clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

17 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Israel
  • Rambam

    Haifa, Israel

United States
  • Ucla Medical Center

    Los Angeles, California, United States

  • Los Robles

    Thousand Oaks, California, United States

  • Tenet Health

    Coral Springs, Florida, United States

  • Baptist Health Research Institute

    Jacksonville, Florida, United States

  • Baptist Health South Florida

    Miami, Florida, United States

  • University of Miami

    Miami, Florida, United States

  • Wellstar Research Institute

    Marietta, Georgia, United States

  • University of Iowa

    Iowa City, Iowa, United States

  • University of Massachusetts

    Worcester, Massachusetts, United States

  • Maimonides Medical Center

    Brooklyn, New York, United States

  • University of Buffalo

    Buffalo, New York, United States

  • Riverside Methodist Hospital

    Columbus, Ohio, United States

  • Mercy Health

    Toledo, Ohio, United States

  • Oregon Health & Science University

    Portland, Oregon, United States

  • Upmc

    Pittsburgh, Pennsylvania, United States

  • Vbmc Harlingen

    Harlingen, Texas, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study. It may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
9 May 2018
Primary completion
15 Apr 2020
Completion
30 Jun 2020
Last update posted
8 May 2024
Registered enrollment
160
Registry id
NCT03474549
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.